Isoform-Selective HDAC Inhibitor Therapy for Transplantation (original) (raw)

The 18 known mammalian histone/protein deacetylases (HDACs) are divided into 4 groups, termed class I (HDAC1, HDAC2, HDAC3, HDAC8), class IIa (HDAC4, HDAC5, HDAC7, HDAC9), class IIb (HDAC6, HDAC10), class III (SIRT1-7) and class IV (HDAC11) enzymes 1. While these enzymes were initially defined by their ability to deacetylate histones and dampen histone-DNA and histone-protein interactions, they are now recognized as regulating the functions of thousands of nonhistone proteins 2. A large number of broadly active pharmacologic HDAC inhibitors (pan-HDACi) have been developed and are in clinical trials as anti-cancer agents due to their abilities to promote tumor cell-cycle arrest, differentiation and apoptosis 3. There is also interest in the potential use of HDACi therapy for autoimmunity and transplantation, but there are concerns that the various pan-HDACi compounds may be too broadly acting and/or toxic for clinical use beyond oncology.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact